Deciphera pharmaceuticals, inc. (DCPH)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Net loss

-217,672

-192,256

-157,299

-125,578

-125,808

-99,854

-87,467

-75,070

-64,005

-50,284

0

0

0

Adjustments to reconcile net loss to net cash flows used in operating activities:
Stock-based compensation expense

21,175

20,410

17,870

15,755

13,880

9,688

9,727

8,125

6,487

4,866

0

0

0

Depreciation expense

1,156

800

467

386

348

300

317

268

225

200

0

0

0

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-10

0

0

0

Net accretion of discounts on marketable securities

5,045

3,999

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

11,638

10,321

2,966

3,714

2,787

5,770

4,063

1,641

579

637

0

0

0

Operating lease assets

-1,343

-958

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

-278

10,862

8,719

7,358

5,478

3,991

3,199

4,683

5,043

2,904

0

0

0

Accrued expenses and other current liabilities

14,752

24,189

14,678

9,444

5,795

4,477

0

0

0

-

-

-

0

Operating lease liabilities

-726

-319

0

0

0

-

-

-

-

-

-

-

-

Other long-term liabilities

250

350

506

569

473

368

194

31

-3

13

0

0

0

Net cash flows used in operating activities

-196,660

-149,296

-120,331

-122,072

-103,095

-86,783

-72,668

-56,602

-45,979

-36,702

0

0

0

Cash flows from investing activities:
Purchases of marketable securities

841,062

817,142

0

0

0

-

-

-

-

-

-

-

-

Maturities of marketable securities

464,336

261,216

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

5,563

4,935

3,513

763

1,015

1,125

952

938

523

406

0

0

0

Increase in restricted investments

1,055

441

0

0

0

-

-

-

-

-

-

-

-

Net cash flows used in investing activities

-282,564

-460,522

-462,505

-167,911

-181,691

-2,194

-2,021

-2,007

-523

-406

0

0

0

Cash flows from financing activities:
Proceeds from public offerings, net of underwriting discounts and commissions

0

-

-

-

0

-

-

-

-

-

-

-

-

Repayment of notes payable to related party

1,263

1,294

187

187

172

187

187

187

187

187

0

0

0

Payments of public offering costs

0

-

-

-

0

-

-

-

-

4,395

0

0

0

Proceeds from exercise of stock options

7,308

5,888

3,813

1,428

2,054

915

0

0

0

-

-

-

-

Net cash flows provided by financing activities

626,648

436,374

435,673

693

187,141

185,987

313,415

311,144

176,416

176,401

0

0

0

Net increase (decrease) in cash and cash equivalents

147,424

-173,444

-147,163

-289,290

-97,645

97,010

238,726

252,535

129,914

139,293

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

54

67

75

79

75

84

87

89

92

95

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities

0

-

-

-

0

-

-

-

0

-

-

-

-

Offering costs included in accounts payable and accrued expenses and other current liabilities

0

-

-

-

0

-

-

-

-

0

0

0

0